Richard Gorlick, MD

Peer-Reviewed Articles

1. Hu, J, Singh, H, Jin, Y, Zhang, W, Wang, J, Xia, X, Somaiah, N, Gorlick, R, Li, S. Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. Proceedings of the National Academy of Sciences of the United States of America 122(41), 2025. e-Pub 2025. PMID: 41052334.
2. Wang J, Ferrena A, Zhang R, Singh S, Viscarret V, Al-Harden W, Aldahamsheh O, Borjihan H, Singla A, Yaguare S, Tingling J, Zi X, Lo Y, Gorlick R, Schwartz EL, Zhao H, Yang R, Geller DS, Zheng D, Hoang BH. Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma. Oncogene. e-Pub 2024. PMID: 38355807.
3. Hu J, Lazar AJ, Ingram D, Wang WL, Zhang W, Jia Z, Ragoonanan D, Wang J, Xia X, Mahadeo K, Gorlick R, Li S. Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models. J Immunother Cancer 12(1), 2024. e-Pub 2024. PMID: 38199607.
4. Truong, DD, Lamhamedi-Cherradi, SE, Porter, RW, Krishnan, S, Swaminathan, J, Gibson, A, Lazar, A, Livingston, JA, Gopalakrishnan, V, Gordon, N, Daw Bitar, N, Navin, N, Gorlick, R, Ludwig, JA. Dissociation protocols used for sarcoma tissues bias the transcriptome observed in single-cell and single-nucleus RNA sequencing. BMC cancer 23(1), 2023. e-Pub 2023. PMID: 37254069.
5. Phadnis S, Wang X, Daw NC, Herzog CE, Subbiah IM, Zaky W, Gouda MA, Morani AC, Amini B, Harrison DJ, Piha-Paul SA, Meric-Bernstam F, Gorlick R, Schwartz CL, Subbiah V. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO Open 8(6):101609, 2023. e-Pub 2023. PMID: 37879233.
6. Cash T, Krailo MD, Buxton AB, Pawel BR, Healey JH, Binitie O, Marcus KJ, Grier HE, Grohar PJ, Reed DR, Weiss AR, Gorlick R, Janeway KA, DuBois SG, Womer RB. Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. J Clin Oncol 41(30):4724-4728, 2023. e-Pub 2023. PMID: 37651654.
7. Yang DM, Zhou Q, Furman-Cline L, Cheng X, Luo D, Lai H, Li Y, Jin KW, Yao B, Leavey PJ, Rakheja D, Lo T, Hall D, Barkauskas DA, Shulman DS, Janeway K, Khanna C, Gorlick R, Menzies C, Zhan X, Xiao G, Skapek SX, Xu L, Klesse LJ, Crompton BD, Xie Y. Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research. JCO Clin Cancer Inform 7:e2300104, 2023. e-Pub 2023. PMID: 37956387.
8. Gianferante DM, Moore A, Spector LG, Wheeler W, Yang T, Hubbard A, Gorlick R, Patiño-Garcia A, Lecanda F, Flanagan AM, Amary F, Andrulis IL, Wunder JS, Thomas DM, Ballinger ML, Serra M, Hattinger C, Demerath E, Johnson W, Birmann BM, De Vivo I, Giles G, Teras LR, Arslan A, Vermeulen R, Sample J, Freedman ND, Huang WY, Chanock SJ, Savage SA, Berndt SI, Mirabello L. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma. Cancer Epidemiol:102432. e-Pub 2023. PMID: 37596165.
9. DuBois SG, Krailo MD, Glade-Bender J, Buxton A, Laack N, Randall RL, Chen HX, Seibel NL, Boron M, Terezakis S, Hill-Kayser C, Hayes A, Reid JM, Teot L, Rakheja D, Womer R, Arndt C, Lessnick SL, Crompton BD, Kolb EA, Daldrup-Link H, Eutsler E, Reed DR, Janeway KA, Gorlick RG. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol 41(11):2098-2107, 2023. e-Pub 2023. PMID: 36669140.
10. Ahmed SK, Witten BG, Harmsen WS, Rose PS, Krailo M, Marcus KJ, Randall RL, DuBois SG, Janeway KA, Womer RB, Grier HE, Gorlick RG, Laack NNI. Analysis of local control outcomes and clinical prognostic factors in localized pelvic Ewing sarcoma patients treated with radiation therapy: A Report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 115(2):337-346, 2023. e-Pub 2023. PMID: 36302496.
11. Moyers JT, Carmagnani Pestana R, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap T, Karp D, Rodon J, Livingston JA, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. e-Pub 2022. PMID: 36288393.
12. Harrison D, Gill J, Roth M, Hingorani P, Zhang W, Teicher B, Earley E, Erickson S, Gatto G, Kumasheva R, Houghton P, Smith M, Anders Kolb E, Gorlick R. Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma. Pediatr Blood Cancer:e30017. e-Pub 2022. PMID: 36250964.
13. Metts JL, Trucco M, Weiser DA, Thompson P, Sandler E, Smith T, Crimella J, Sansil S, Thapa R, Fridley BL, Llosa N, Badgett T, Gorlick R, Reed D, Gill J. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. Cancer Med. e-Pub 2022. PMID: 36151773.
14. Yang Q, Hu J, Jia Z, Wang Q, Wang J, Dao LH, Zhang W, Zhang S, Xia X, Gorlick R, Li S. Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma. Clin Cancer Res 28(17):3862-3873, 2022. e-Pub 2022. PMID: 35727602.
15. Hingorani P, Zhang W, Zhang Z, Xu Z, Wang WL, Roth ME, Wang Y, Gill JB, Harrison DJ, Teicher BA, Erickson SW, Gatto G, Kolb EA, Smith MA, Kurmasheva RT, Houghton PJ, Gorlick R. Trastuzumab deruxtecan, antibody-drug conjugate targeting HER2, is effective in pediatric solid tumors: A report by the Pediatric Preclinical Testing Consortium. Mol Cancer Ther 21(8):1318-1325, 2022. e-Pub 2022. PMID: 35657346.
16. Wang Y, Tian X, Zhang W, Zhang Z, Lazcano R, Hingorani P, Roth ME, Gill JD, Harrison DJ, Xu Z, Jusu S, Kannan S, Wang J, Lazar AJ, Earley EJ, Erickson SW, Gelb T, Huxley P, Lahdenranta J, Mudd G, Kurmasheva RT, Houghton PJ, Smith MA, Kolb EA, Gorlick R. Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. Mol Cancer Ther 21(6):903-913, 2022. e-Pub 2022. PMID: 35312779.
17. Cash T, Krailo MD, Buxton A, Pawel B, Healey JH, Binitie O, Marcus KC, Grier HE, DuBois SG, Grohar P, Reed DR, Weiss AR, Gorick RG, Janeway KA, Womer RB. Long-term outcomes in patients with localized Ewing sarcoma treated with interval-compressed chemotherapy: A long-term follow-up report from Children’s Oncology Group study AEWS0031. Journal of Clinical Oncology, 2022. e-Pub 2022.
18. Skaidrite Ilcisin LA, Han R, Krailo MD, Gorlick RG, Nadel HR, Binitie O, Janeway KA, Bona K. Poverty, race, ethnicity, and survival among U.S. children with non-metastatic osteosarcoma treated on EURAMOS-1: A report from the Children’s Oncology Group. Journal of Clinical Oncology 40(16). e-Pub 2022.
19. Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao Q, Dao L, Xia X, Natalie Wall F, Zhang Z, Mahadeo K, Gorlick R, Kopetz S, Dotti G, Li S. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. J Immunother Cancer 10(1), 2022. e-Pub 2022. PMID: 35027427.
20. Leavey PJ, Laack NN, Krailo MD, Buxton A, Randall RL, DuBois SG, Reed DR, Grier HE, Hawkins DS, Pawel B, Nadel H, Womer RB, Letson GD, Bernstein M, Brown K, Maciej A, Chuba P, Ahmed AA, Indelicato DJ, Wang D, Marina N, Gorlick R, Janeway KA, Mascarenhas L. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. J Clin Oncol 39(36):JCO2100358, 2021. e-Pub 2021. PMID: 34652968.
21. DuBois SG, Krailo MD, Buxton A, Lessnick SL, Teot LA, Rakheja D, Crompton BD, Janeway KA, Gorlick RG, Glade-Bender J. Patterns of Translocation Testing in Patients Enrolling to a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. Arch Pathol Lab Med 145(12):1564-1568, 2021. e-Pub 2021. PMID: 33769463.
22. Collier AB, Krailo MD, Dang HM, DuBois SG, Hawkins DS, Bernstein ML, Bomgaars LR, Reed DR, Gorlick RG, Janeway KA. Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group. Pediatr Blood Cancer 68(12):e29333, 2021. e-Pub 2021. PMID: 34496122.
23. Lamhamedi-Cherradi SE, Mohiuddin S, Mishra DK, Krishnan S, Velasco AR, Vetter AM, Pence K, McCall D, Truong DD, Cuglievan B, Menegaz BA, Utama B, Daw NC, Molina ER, Zielinski RJ, Livingston JA, Gorlick R, Mikos AG, Kim MP, Ludwig JA. Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Ther 28(12):1325-1338, 2021. e-Pub 2021. PMID: 33408328.
24. Kurmasheva RT, Erickson SW, Han R, Teicher BA, Smith MA, Roth M, Gorlick R, Houghton PJ. In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC). Pediatr Blood Cancer 68(11):e29304, 2021. e-Pub 2021. PMID: 34453478.
25. Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer 68(9):e29188, 2021. e-Pub 2021. PMID: 34137164.
26. Zhou X, Beilter A, Xu Z, Gao R, Xiong S, Paulucci-Holthauzen A, Lozano G, de Crombrugghe B, Gorlick R. Wnt/ß-catenin-mediated p53 suppression is indispensable for osteogenesis of mesenchymal progenitor cells. Cell Death Dis 12(6):521, 2021. e-Pub 2021. PMID: 34021120.
27. Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA, Erickson SW, Earley EJ, Mosse YP, Martinez D, Pogoriler J, Krytska K, Patel K, Groff D, Tsang M, Ghilu S, Wang Y, Seaman S, Feng Y, Croix BS, Gorlick R, Kurmasheva R, Houghton PJ, Maris JM. The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Clin Cancer Res 27(10):2938-2946, 2021. e-Pub 2021. PMID: 33619171.
28. Wang J, Aldahamsheh O, Ferrena A, Borjihan H, Singla A, Yaguare S, Singh S, Viscarret V, Tingling J, Zi X, Lo Y, Gorlick R, Zheng D, Schwartz EL, Zhao H, Yang R, Geller DS, Hoang BH. The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma. Ann N Y Acad Sci 1490(1):90-104, 2021. e-Pub 2021. PMID: 33594717.
29. Hingorani P, Roth ME, Wang Y, Zhang W, Gill JB, Harrison DJ, Teicher B, Erickson S, Gatto G, Smith MA, Kolb EA, Gorlick R. ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. Mol Cancer Ther 20(3):535-540, 2021. e-Pub 2021. PMID: 33298592.
30. Nevil G, Roth M, Gill J, Zhang W, Teicher B, Erickson SW, Gatto G, Smith M, Kolb EA, Gorlick R. Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. Pediatr Hematol Oncol 38(1):8-13, 2021. e-Pub 2021. PMID: 32804009.
31. Dao L, Ragoonanan D, Batth I, Satelli A, Foglesong J, Wang J, Zaky W, Gill JB, Liu D, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman E, Gorlick R, Daw N, Li S. Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas. Front Oncol 11:760267, 2021. e-Pub 2021. PMID: 34956881.
32. Zvi Y, Ugur E, Batko B, Gill J, Roth M, Gorlick R, Hall D, Tingling J, Barkauskas DA, Zhang J, Yang R, Hoang BH, Geller DS. Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. Sarcoma 2021:8324348, 2021. e-Pub 2021. PMID: 33603563.
33. Wang J, Sato K, O'Donnell E, Singla A, Yaguare S, Aldahamsheh O, Batko B, Borjihan H, Tingling J, Zhang J, Weiser DA, Loeb DM, Gorlick R, Schwartz EL, Yang R, Zi X, Zhao H, Geller DS, Hoang BH. Skp2 depletion reduces tumor-initiating properties and promotes apoptosis in synovial sarcoma. Transl Oncol 13(10):100809, 2020. e-Pub 2020. PMID: 32623326.
34. Gill J, Zhang W, Zhang Z, Roth M, Harrison DJ, Rowshan S, Erickson S, Gatto G, Kurmasheva R, Houghton P, Teicher B, Smith MA, Kolb EA, Gorlick R. Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. Pediatr Blood Cancer 67(10):e28606, 2020. e-Pub 2020. PMID: 32706456.
35. Peterson HM, Tank A, Geller DS, Yang R, Gorlick R, Hoang BH, Roblyer D. Characterization of bony anatomic regions in pediatric and adult healthy volunteers using diffuse optical spectroscopic imaging. J Biomed Opt 25(8):1-17, 2020. e-Pub 2020. PMID: 32790252.
36. Batth IS, Meng Q, Wang Q, Torres KE, Burks J, Wang J, Gorlick R, Li S. Rare osteosarcoma cell subpopulation protein array and profiling using imaging mass cytometry and bioinformatics analysis. BMC Cancer 20(1):715, 2020. e-Pub 2020. PMID: 32736533.
37. Harrison DJ, Gill JD, Roth ME, Zhang W, Teicher B, Erickson S, Gatto G, Kurmasheva RT, Houghton PJ, Smith MA, Kolb EA, Gorlick R. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. Pediatr Blood Cancer 67(6):e28222, 2020. e-Pub 2020. PMID: 32207565.
38. Kolb EA, Houghton PJ, Kurmasheva RT, Mosse YP, Maris JM, Erickson SW, Guo Y, Teicher BA, Smith MA, Gorlick R. Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report. Pediatr Blood Cancer 67(5):e28098, 2020. e-Pub 2020. PMID: 31975571.
39. Mirabello L, Zhu B, Koster R, Karlins E, Dean M, Yeager M, Gianferante M, Spector LG, Morton LM, Karyadi D, Robison LL, Armstrong GT, Bhatia S, Song L, Pankratz N, Pinheiro M, Gastier-Foster JM, Gorlick R, de Toledo SRC, Petrilli AS, Patino-Garcia A, Lecanda F, Gutierrez-Jimeno M, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Kurucu N, Ilhan IE, Ballinger ML, Thomas DM, Barkauskas DA, Mejia-Baltodano G, Valverde P, Hicks BD, Zhu B, Wang M, Hutchinson AA, Tucker M, Sampson J, Landi MT, Freedman ND, Gapstur S, Carter B, Hoover RN, Chanock SJ, Savage SA. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncol. e-Pub 2020. PMID: 32191290.
40. Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA. Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008, 2020. e-Pub 2020. PMID: 32081846.
41. Kinnaman MD, Zhu C, Weiser DA, Mohiuddin S, Hingorani P, Roth M, Gill J, Janeway KA, Gorlick R, Lessnick SL, Grohar PJ. Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group. Sarcoma 2020:3498549, 2020. e-Pub 2020. PMID: 33488267.
42. Hu J, Xia X, Gorlick R, Li S. Induction of NKG2D ligand expression on tumor cells by CD8+ T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor. Oncogene 38(49):7433-7446, 2019. e-Pub 2019. PMID: 31427736.
43. Wang Y, Liang W, Qu S, Zhang Y, Du Z, Ji T, Qu H, Gorlick R, Guo W. Assessment of patient experiences following total sacrectomy for primary malignant sacral tumors: A qualitative study. J Surg Oncol 120(8):1497-1504, 2019. e-Pub 2019. PMID: 31705571.
44. Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, Brichard B, Claude L, Craft A, Amler S, Gaspar N, Gelderblom H, Goldsby R, Gorlick R, Grier HE, Guinbretiere JM, Hauser P, Hjorth L, Janeway K, Juergens H, Judson I, Krailo M, Kruseova J, Kuehne T, Ladenstein R, Lervat C, Lessnick SL, Lewis I, Linassier C, Marec-Berard P, Marina N, Morland B, Pacquement H, Paulussen M, Randall RL, Ranft A, Le Teuff G, Wheatley K, Whelan J, Womer R, Oberlin O, Hawkins DS, Euro-EWING, Investigators E. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol 37(34):3192-3202, 2019. e-Pub 2019. PMID: 31553693.
45. Levine NL, Zhang Y, Hoang BH, Yang R, Jurkowski ZH, Roth ME, Gill JB, Lo Y, Eisenberg RE, Bekarev M, Gorlick R, Geller DS. LigaSure Use Decreases Intraoperative Blood Loss Volume and Blood Transfusion Volume in Sarcoma Surgery. J Am Acad Orthop Surg 27(22):841-847, 2019. e-Pub 2019. PMID: 30889038.
46. Rokita JL, Rathi KS, Cardenas MF, Upton KA, Jayaseelan J, Cross KL, Pfeil J, Egolf LE, Way GP, Farrel A, Kendsersky NM, Patel K, Gaonkar KS, Modi A, Berko ER, Lopez G, Vaksman Z, Mayoh C, Nance J, McCoy K, Haber M, Evans K, McCalmont H, Bendak K, Böhm JW, Marshall GM, Tyrrell V, Kalletla K, Braun FK, Qi L, Du Y, Zhang H, Lindsay HB, Zhao S, Shu J, Baxter P, Morton C, Kurmashev D, Zheng S, Chen Y, Bowen J, Bryan AC, Leraas KM, Coppens SE, Doddapaneni H, Momin Z, Zhang W, Sacks GI, Hart LS, Krytska K, Mosse YP, Gatto GJ, Sanchez Y, Greene CS, Diskin SJ, Vaske OM, Haussler D, Gastier-Foster JM, Kolb EA, Gorlick R, Li XN, Reynolds CP, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Raman P, Wheeler DA, Maris JM. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep 29(6):1675-1689.e9, 2019. e-Pub 2019. PMID: 31693904.
47. Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, Hawthorne T, Crowley E, Moscow JA, Reid JM, Villalobos V, Randall RL, Gorlick R, Janeway KA. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. Eur J Cancer 121:177-183, 2019. e-Pub 2019. PMID: 31586757.
48. Karkare S, Allen KJH, Jiao R, Malo ME, Dawicki W, Helal M, Godson DL, Dickinson R, MacDonald-Dickinson V, Yang R, Hoang B, Gorlick R, Geller DS, Dadachova E. Detection and targeting insulin growth factor receptor type 2 (IGF2R) in osteosarcoma PDX in mouse models and in canine osteosarcoma tumors. Sci Rep 9(1):11476, 2019. e-Pub 2019. PMID: 31391495.
49. Zhao Q, Hu J, Mitra A, Cutrera J, Zhang W, Zhang Z, Yan J, Xia X, Mahadeo KM, Livingston JA, Gorlick R, Li S. Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. J Immunother Cancer 7(1):154, 2019. e-Pub 2019. PMID: 31208461.
50. Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. Clin Cancer Res 25(7):2278-2289, 2019. e-Pub 2019. PMID: 30563935.
51. Currier AW, Kolb EA, Gorlick RG, Roth ME, Gopalakrishnan V, Sampson VB. p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma. Sci Rep 9(1):6161, 2019. e-Pub 2019. PMID: 30992462.
52. Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD. Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer 120(8):869, 2019. e-Pub 2019. PMID: 30880335.
53. Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 109:36-50, 2019. e-Pub 2019. PMID: 30685685.
54. Isakoff MS, Goldsby R, Villaluna D, Krailo MD, Hingorani P, Collier A, Morris CD, Kolb EA, Doski JJ, Womer RB, Gorlick R, Janeway KA. A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 66(2):e27524, 2019. e-Pub 2019. PMID: 30378256.
55. Spraker-Perlman HL, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Doski J, Gorlick R, Janeway KA, Isakoff MS. Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 66(1):e27444, 2019. e-Pub 2019. PMID: 30255612.
56. Kopp LM, Womer RB, Schwartz CL, Ebb DH, Franco VI, Hall D, Barkauskas DA, Krailo MD, Grier HE, Meyers PA, Wexler LH, Marina NM, Janeway KA, Gorlick R, Bernstein ML, Lipshultz SE, Group CO. Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group. Cardiooncology 5:15, 2019. e-Pub 2019. PMID: 32154021.
57. Ferrari A, Gasparini P, Gill J, Gorlick R. Challenges of Clinical Management of Adolescent and Young Adults With Bone and Soft Tissue Sarcoma. Cancer J 24(6):301-306, 2018. e-Pub 2018. PMID: 30480574.
58. Gorlick R, Janeway KA, Adamson PC. Dose Intensification Improves the Outcome of Ewing Sarcoma. J Clin Oncol:JCO2018793489. e-Pub 2018. PMID: 30204546.
59. Zhang Y, Zvi YS, Batko B, Zaphiros N, O'Donnell EF, Wang J, Sato K, Yang R, Geller DS, Koirala P, Zhang W, Du X, Piperdi S, Liu Y, Zheng D, Roth M, Gill J, Zhang J, Ren T, Gorlick R, Zi X, Hoang BH. Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma. Sci Rep 8(1):14294, 2018. e-Pub 2018. PMID: 30250282.
60. Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer 119(5):615-621, 2018. e-Pub 2018. PMID: 30131550.
61. Yedururi S, Chawla S, Amini B, Wei W, Salem UI, Morani AC, Wang WL, Gorlick R, Lewis VO, Daw NC. Tumor thrombus in the large veins draining primary pelvic osteosarcoma on cross sectional imaging. Eur J Radiol 105:49-55, 2018. e-Pub 2018. PMID: 30017298.
62. Koster R, Panagiotou OA, Wheeler WA, Karlins E, Gastier-Foster JM, Caminada de Toledo SR, Petrilli AS, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Lecanda F, Serra M, Hattinger C, Picci P, Scotlandi K, Thomas DM, Ballinger ML, Gorlick R, Barkauskas DA, Spector LG, Tucker M, Belynda DH, Yeager M, Hoover RN, Wacholder S, Chanock SJ, Savage SA, Mirabello L. Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. Int J Cancer 142(8):1594-1601, 2018. e-Pub 2018. PMID: 29210060.
63. Shaul E, Roth M, Lo Y, Geller DS, Hoang B, Yang R, Malkin D, Gorlick R, Gill J. Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma. Cancer 124(6):1242-1250, 2018. e-Pub 2018. PMID: 29313943.
64. Zhu C, Olson KA, Roth M, Geller DS, Gorlick RG, Gill J, Laack NN, Randall RL. Provider views on the management of Ewing sarcoma of the spine and pelvis. J Surg Oncol 117(3):417-424, 2018. e-Pub 2018. PMID: 29044582.
65. Barris DM, Weiner SB, Dubin RA, Fremed M, Zhang X, Piperdi S, Zhang W, Maqbool S, Gill J, Roth M, Hoang B, Geller D, Gorlick R, Weiser DA. Detection of circulating tumor DNA in patients with osteosarcoma. Oncotarget 9(16):12695-12704, 2018. e-Pub 2018. PMID: 29560102.
66. Ahmed SK, Randall RL, DuBois SG, Harmsen WS, Krailo M, Marcus KJ, Janeway KA, Geller DS, Sorger JI, Womer RB, Granowetter L, Grier HE, Gorlick RG, Laack NNI. Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys 99(5):1286-1294, 2017. e-Pub 2017. PMID: 28964585.
67. Peterson HM, Hoang BH, Geller D, Yang R, Gorlick R, Berger J, Tingling J, Roth M, Gill J, Roblyer D. In vivo, noninvasive functional measurements of bone sarcoma using diffuse optical spectroscopic imaging. J Biomed Opt 22(12):1-9, 2017. e-Pub 2017. PMID: 29264893.
68. Ren T, Piperdi S, Koirala P, Park A, Zhang W, Ivenitsky D, Zhang Y, Villanueva-Siles E, Hawkins DS, Roth M, Gorlick R. CD49b inhibits osteogenic differentiation and plays an important role in osteosarcoma progression. Oncotarget 8(50):87848-87859, 2017. e-Pub 2017. PMID: 29152125.
69. Lock R, Carol H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Purmal A, Gudkov A, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer 64(4), 2017. e-Pub 2017. PMID: 27650817.
70. Kurmasheva RT, Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Kang M, Reynolds CP, Wu J, Houghton PJ, Smith MA. Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64(4), 2017. e-Pub 2017. PMID: 27786412.
71. Yang Y, Yang R, Roth M, Piperdi S, Zhang W, Dorfman H, Rao P, Park A, Tripathi S, Freeman C, Zhang Y, Sowers R, Rosenblum J, Geller D, Hoang B, Gill J, Gorlick R. Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model. Genes Cancer 8(1-2):484-494, 2017. e-Pub 2017. PMID: 28435520.
72. Glover J, Man TK, Barkauskas DA, Hall D, Tello T, Sullivan MB, Gorlick R, Janeway K, Grier H, Lau C, Toretsky JA, Borinstein SC, Khanna C, Fan TM, Group COG. Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation. PLoS One 12(7):e0181204, 2017. e-Pub 2017. PMID: 28732082.
73. Gill J, Connolly P, Roth M, Chung SH, Zhang W, Piperdi S, Hoang B, Yang R, Guzik H, Morris J, Gorlick R, Geller DS. The effect of bone morphogenetic protein-2 on osteosarcoma metastasis. PLoS One 12(3):e0173322, 2017. e-Pub 2017. PMID: 28264040.
74. Cohen B, Roth M, Marron JM, Gray SW, Geller DS, Hoang B, Gorlick R, Janeway KA, Gill J. Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Ann Surg Oncol 23(Suppl 5):990-997, 2016. e-Pub 2016. PMID: 27459981.
75. Geller DS, Morris J, Revskaya E, Kahn M, Zhang W, Piperdi S, Park A, Koirala P, Guzik H, Hall C, Hoang B, Yang R, Roth M, Gill J, Gorlick R, Dadachova E. Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R). Nucl Med Biol 43(12):812-817, 2016. e-Pub 2016. PMID: 27744117.
76. Sampson VB, Vetter NS, Zhang W, Patil PU, Mason RW, George E, Gorlick R, Kolb EA. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. Oncotarget. e-Pub 2016. PMID: 27863409.
77. Daw NC, Laack NN, McIlvaine EJ, Krailo M, Womer RB, Granowetter L, Grier HE, Marina NM, Bernstein ML, Gebhardt MC, Marcus KJ, Advani SM, Healey JH, Letson GD, Gorlick RG, Randall RL. Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group. Ann Surg Oncol 23(11):3541-7, 2016. e-Pub 2016. PMID: 27216741.
78. Bishop MW, Chang YC, Krailo MD, Meyers PA, Provisor AJ, Schwartz CL, Marina NM, Teot LA, Gebhardt MC, Gorlick R, Janeway KA, Chou AJ. Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 63(10):1737-43, 2016. e-Pub 2016. PMID: 27128693.
79. Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KL, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PC, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MC, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 17(10):1396-1408, 2016. e-Pub 2016. PMID: 27569442.
80. Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, Houghton PJ. Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Res 76(19):5798-5809, 2016. e-Pub 2016. PMID: 27496711.
81. Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E, Pápai Z, Rubino J, Pathiraja K, Hille DA, Ayers M, Yao SL, Nebozhyn M, Lu B, Mauro D. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer 63(10):1761-70, 2016. e-Pub 2016. PMID: 27362300.
82. Kang MH, Reynolds CP, Kolb EA, Gorlick R, Carol H, Lock R, Keir ST, Maris JM, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63(10):1744-52, 2016. e-Pub 2016. PMID: 27238606.
83. Lagmay JP, Krailo MD, Dang H, Kim A, Hawkins DS, Beaty O, Widemann BC, Zwerdling T, Bomgaars L, Langevin AM, Grier HE, Weigel B, Blaney SM, Gorlick R, Janeway KA. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. J Clin Oncol 34(25):3031-8, 2016. e-Pub 2016. PMID: 27400942.
84. Koirala P, Roth ME, Gill J, Chinai JM, Ewart MR, Piperdi S, Geller DS, Hoang BH, Fatakhova YV, Ghorpade M, Zang X, Gorlick R. HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. Sci Rep 6:31154, 2016. e-Pub 2016. PMID: 27531281.
85. Vo KT, Edwards JV, Epling CL, Sinclair E, Hawkins DS, Grier HE, Janeway KA, Barnette P, McIlvaine E, Krailo MD, Barkauskas DA, Matthay KK, Womer RB, Gorlick RG, Lessnick SL, Mackall CL, DuBois SG. Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clin Cancer Res 22(14):3643-50, 2016. e-Pub 2016. PMID: 26861456.
86. Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, Hoang BH, Park A, Fremed MA, Zang X, Gorlick R. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep 6:30093, 2016. e-Pub 2016. PMID: 27456063.
87. Mascarenhas L, Felgenhauer JL, Bond MC, Villaluna D, Femino JD, Laack NN, Ranganathan S, Meyer J, Womer RB, Gorlick R, Krailo MD, Marina N. Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer 63(3):493-8, 2016. e-Pub 2016. PMID: 26579879.
88. Morris CD, Teot LA, Bernstein ML, Marina N, Krailo MD, Villaluna D, Janeway KA, DuBois SG, Gorlick RG, Randall RL. Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. J Surg Oncol 113(4):351-4, 2016. e-Pub 2016. PMID: 26776342.
89. Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Reynolds CP, Kang MH, Billups CA, Collins J, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA. Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63(3):443-50, 2016. e-Pub 2016. PMID: 26797892.
90. Shin MH, He Y, Marrogi E, Piperdi S, Ren L, Khanna C, Gorlick R, Liu C, Huang J. A RUNX2-Mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells. PLoS Genet 12(2):e1005884, 2016. e-Pub 2016. PMID: 26925584.
91. Attiyeh EF, Maris JM, Lock R, Reynolds CP, Kang MH, Carol H, Gorlick R, Kolb EA, Keir ST, Wu J, Landesman Y, Shacham S, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatr Blood Cancer 63(2):276-86, 2016. e-Pub 2016. PMID: 26398108.
92. Yang R, Piperdi S, Zhang Y, Zhu Z, Neophytou N, Hoang BH, Mason G, Geller D, Dorfman H, Meyers PA, Healey JH, Phinney DG, Gorlick R. Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma. Clin Orthop Relat Res 474(1):178-89, 2016. e-Pub 2016. PMID: 26463566.
93. Roth M, Barris DM, Piperdi S, Kuo V, Everts S, Geller D, Houghton P, Kolb EA, Hawthorne T, Gill J, Gorlick R. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatr Blood Cancer 63(1):32-8, 2016. e-Pub 2016. PMID: 26305408.
94. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, Amundadottir LT, Figueroa JD, Landi MT, Mirabello L, Savage SA, Taylor PR, De Vivo I, McGlynn KA, Purdue MP, Rajaraman P, Adami HO, Ahlbom A, Albanes D, Amary MF, An SJ, Andersson U, Andriole G, Andrulis IL, Angelucci E, Ansell SM, Arici C, Armstrong BK, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Becker N, Benavente Y, Benhamou S, Berg C, Van Den Berg D, Bernstein L, Bertrand KA, Birmann BM, Black A, Boeing H, Boffetta P, Boutron-Ruault MC, Bracci PM, Brinton L, Brooks-Wilson AR, Bueno-de-Mesquita HB, Burdett L, Buring J, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Carrato A, Carreon T, Carta A, Chan JK, Chang ET, Chang GC, Chang IS, Chang J, Chang-Claude J, Chen CJ, Chen CY, Chen C, Chen CH, Chen C, Chen H, Chen K, Chen KY, Chen KC, Chen Y, Chen YH, Chen YS, Chen YM, Chien LH, Chirlaque MD, Choi JE, Choi YY, Chow WH, Chung CC, Clavel J, Clavel-Chapelon F, Cocco P, Colt JS, Comperat E, Conde L, Connors JM, Conti D, Cortessis VK, Cotterchio M, Cozen W, Crouch S, Crous-Bou M, Cussenot O, Davis FG, Ding T, Diver WR, Dorronsoro M, Dossus L, Duell EJ, Ennas MG, Erickson RL, Feychting M, Flanagan AM, Foretova L, Fraumeni JF, Freedman ND, Beane Freeman LE, Fuchs C, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, García-Closas R, Gascoyne RD, Gastier-Foster J, Gaudet MM, Gaziano JM, Giffen C, Giles GG, Giovannucci E, Glimelius B, Goggins M, Gokgoz N, Goldstein AM, Gorlick R, Gross M, Grubb R, Gu J, Guan P, Gunter M, Guo H, Habermann TM, Haiman CA, Halai D, Hallmans G, Hassan M, Hattinger C, He Q, He X, Helzlsouer K, Henderson B, Henriksson R, Hjalgrim H, Hoffman-Bolton J, Hohensee C, Holford TR, Holly EA, Hong YC, Hoover RN, Horn-Ross PL, Hosain GM, Hosgood HD, Hsiao CF, Hu N, Hu W, Hu Z, Huang MS, Huerta JM, Hung JY, Hutchinson A, Inskip PD, Jackson RD, Jacobs EJ, Jenab M, Jeon HS, Ji BT, Jin G, Jin L, Johansen C, Johnson A, Jung YJ, Kaaks R, et al. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst 107(12):djv279, 2015. e-Pub 2015. PMID: 26464424.
95. Reynolds CP, Kang MH, Maris JM, Kolb EA, Gorlick R, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Pediatr Blood Cancer 62(11):1897-905, 2015. e-Pub 2015. PMID: 26154614.
96. Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, Panagiotou OA, Largaespada D, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, de Toledo SR, Petrilli AS, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Andrulis IL, Wunder JS, Gokgoz N, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Halai D, Ballinger ML, Thomas DM, Davis S, Barkauskas DA, Marina N, Helman L, Otto GM, Becklin KL, Wolf NK, Weg MT, Tucker M, Wacholder S, Fraumeni JF, Caporaso NE, Boland JF, Hicks BD, Vogt A, Burdett L, Yeager M, Hoover RN, Chanock SJ, Savage SA. A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discov 5(9):920-31, 2015. e-Pub 2015. PMID: 26084801.
97. Geller DS, Singh MY, Zhang W, Gill J, Roth ME, Kim MY, Xie X, Singh CK, Dorfman HD, Villanueva-Siles E, Park A, Piperdi S, Gorlick R. Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2. Clin Cancer Res 21(13):3003-12, 2015. e-Pub 2015. PMID: 25472999.
98. Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M, investigators E. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol 33(20):2279-87, 2015. e-Pub 2015. PMID: 26033801.
99. Mirabello L, Yeager M, Mai PL, Gastier-Foster JM, Gorlick R, Khanna C, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Andrulis IL, Wunder JS, Gokgoz N, Barkauskas DA, Zhang X, Vogt A, Jones K, Boland JF, Chanock SJ, Savage SA. Germline TP53 variants and susceptibility to osteosarcoma. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25896519.
100. Houghton PJ, Kurmasheva RT, Kolb EA, Gorlick R, Maris JM, Wu J, Tong Z, Arnold MA, Chatterjee M, Williams TM, Smith MA. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 62(7):1214-21, 2015. e-Pub 2015. PMID: 25809532.
101. Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 62(6):1106-9, 2015. e-Pub 2015. PMID: 25407467.
102. Moriarity BS, Otto GM, Rahrmann EP, Rathe SK, Wolf NK, Weg MT, Manlove LA, LaRue RS, Temiz NA, Molyneux SD, Choi K, Holly KJ, Sarver AL, Scott MC, Forster CL, Modiano JF, Khanna C, Hewitt SM, Khokha R, Yang Y, Gorlick R, Dyer MA, Largaespada DA. A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet 47(6):615-24, 2015. e-Pub 2015. PMID: 25961939.
103. Lerman DM, Monument MJ, McIlvaine E, Liu XQ, Huang D, Monovich L, Beeler N, Gorlick RG, Marina NM, Womer RB, Bridge JA, Krailo MD, Randall RL, Lessnick SL, Biology Committee COGES. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 62(5):759-65, 2015. e-Pub 2015. PMID: 25464386.
104. Bhattasali O, Vo AT, Roth M, Geller D, Randall RL, Gorlick R, Gill J. Variability in the reported management of pulmonary metastases in osteosarcoma. Cancer Med 4(4):523-31, 2015. e-Pub 2015. PMID: 25626877.
105. Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Böhling T, Calaminus G, Capra M, Deffenbaugh C, Dhooge C, Eriksson M, Flanagan AM, Gelderblom H, Goorin A, Gorlick R, Gosheger G, Grimer RJ, Hall KS, Helmke K, Hogendoorn PC, Jundt G, Kager L, Kuehne T, Lau CC, Letson GD, Meyer J, Meyers PA, Morris C, Mottl H, Nadel H, Nagarajan R, Randall RL, Schomberg P, Schwarz R, Teot LA, Sydes MR, Bernstein M, collaborators E. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol 26(2):407-14, 2015. e-Pub 2015. PMID: 25421877.
106. Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 21(4):819-32, 2015. e-Pub 2015. PMID: 25500058.
107. Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 62(1):91-8, 2015. e-Pub 2015. PMID: 25263539.
108. Poon VI, Roth M, Piperdi S, Geller D, Gill J, Rudzinski ER, Hawkins DS, Gorlick R. Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. Clin Sarcoma Res 5(1):4, 2015. e-Pub 2015. PMID: 25642322.
109. Rosenblum JM, Wijetunga NA, Fazzari MJ, Krailo M, Barkauskas DA, Gorlick R, Greally JM. Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status. Epigenetics 10(1):31-9, 2015. e-Pub 2015. PMID: 25531418.
110. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L, Ibrahim A, Hautman C, Raj PS, Abnet CC, Adjei AA, Ahlbom A, Albanes D, Allen NE, Ambrosone C, Aldrich M, Amiano P, Amos C, Andersson U, Andriole G, Andrulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum R, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Bueno-de-Mesquita HB, Buring JE, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Cao G, Caporaso NE, Carrato A, Carreon T, Carta A, Chang GC, Chang IS, Chang-Claude J, Che X, Chen CJ, Chen CY, Chen CH, Chen C, Chen KY, Chen YM, Chokkalingam AP, Chu LW, Clavel-Chapelon F, Colditz GA, Colt JS, Conti D, Cook MB, Cortessis VK, Crawford ED, Cussenot O, Davis FG, De Vivo I, Deng X, Ding T, Dinney CP, Di Stefano AL, Diver WR, Duell EJ, Elena JW, Fan JH, Feigelson HS, Feychting M, Figueroa JD, Flanagan AM, Fraumeni JF, Freedman ND, Fridley BL, Fuchs CS, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gastier-Foster JM, Gaziano JM, Gerhard DS, Giffen CA, Giles GG, Gillanders EM, Giovannucci EL, Goggins M, Gokgoz N, Goldstein AM, Gonzalez C, Gorlick R, Greene MH, Gross M, Grossman HB, Grubb R, Gu J, Guan P, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Hartge P, Hattinger C, Hayes RB, He Q, Helman L, Henderson BE, Henriksson R, Hoffman-Bolton J, Hohensee C, Holly EA, Hong YC, Hoover RN, Hosgood HD, Hsiao CF, Hsing AW, Hsiung CA, Hu N, Hu W, Hu Z, Huang MS, Hunter DJ, Inskip PD, Ito H, Jacobs EJ, Jacobs KB, Jenab M, Ji BT, Johansen C, Johansson M, Johnson A, Kaaks R, Kamat AM, Kamineni A, Karagas M, Khanna C, Khaw KT, Kim C, Kim IS, Kim JH, Kim YH, Kim YC, Kim YT, Kang CH, Jung YJ, Kitahara CM, Klein AP, Klein R, Kogevinas M, Koh WP, Kohno T, Kolonel LN, Kooperberg C, Kratz CP, Krogh V, Kunitoh H, Kurtz RC, Kurucu N, Lan Q, Lathrop M, et al. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet 23(24):6616-33, 2014. e-Pub 2014. PMID: 25027329.
111. Houghton PJ, Kurmasheva RT, Lyalin D, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Smith MA. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatr Blood Cancer 61(11):1972-9, 2014. e-Pub 2014. PMID: 25131802.
112. Kolb EA, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer 61(10):1816-21, 2014. e-Pub 2014. PMID: 24912408.
113. Gorlick R, Barkauskas DA, Krailo M, Piperdi S, Sowers R, Gill J, Geller D, Randall RL, Janeway K, Schwartz C, Grier H, Meyers PA, Gorlick R, Bernstein M, Marina N. HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatr Blood Cancer 61(9):1558-64, 2014. e-Pub 2014. PMID: 24753182.
114. Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res 20(16):4200-9, 2014. e-Pub 2014. PMID: 24803583.
115. Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Lyalin D. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer 61(8):1493-6, 2014. e-Pub 2014. PMID: 24664981.
116. Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer 61(8):1486-9, 2014. e-Pub 2014. PMID: 24623675.
117. Borinstein SC, Barkauskas DA, Bernstein M, Goorin A, Gorlick R, Krailo M, Schwartz CL, Wexler LH, Toretsky JA. Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. Pediatr Blood Cancer 61(4):749-52, 2014. e-Pub 2014. PMID: 24178953.
118. Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61(2):245-52, 2014. e-Pub 2014. PMID: 24038993.
119. Houghton PJ, Kurmasheva RT, Kolb EA, Wu J, Gorlick R, Maris JM, Smith MA. Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61(2):380-2, 2014. e-Pub 2014. PMID: 24019233.
120. Roth M, Linkowski M, Tarim J, Piperdi S, Sowers R, Geller D, Gill J, Gorlick R. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer 120(4):548-54, 2014. e-Pub 2014. PMID: 24166473.
121. Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61(1):158-64, 2014. e-Pub 2014. PMID: 23956067.
122. Cao Y, Roth M, Piperdi S, Montoya K, Sowers R, Rao P, Geller D, Houghton P, Kolb EA, Gill J, Gorlick R. Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma. PLoS One 9(8):e106249, 2014. e-Pub 2014. PMID: 25170759.
123. Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer 60(11):1860-7, 2013. e-Pub 2013. PMID: 23798344.
124. Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 60(8):1325-32, 2013. e-Pub 2013. PMID: 23553917.
125. Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 60(7):E42-5, 2013. e-Pub 2013. PMID: 23303741.
126. Goldsby RE, Fan TM, Villaluna D, Wagner LM, Isakoff MS, Meyer J, Randall RL, Lee S, Kim G, Bernstein M, Gorlick R, Krailo M, Marina N. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Eur J Cancer 49(10):2384-91, 2013. e-Pub 2013. PMID: 23664013.
127. Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Kurucu N, Ilhan IE, Sari N, Serra M, Hattinger C, Picci P, Spector LG, Barkauskas DA, Marina N, de Toledo SR, Petrilli AS, Amary MF, Halai D, Thomas DM, Douglass C, Meltzer PS, Jacobs K, Chung CC, Berndt SI, Purdue MP, Caporaso NE, Tucker M, Rothman N, Landi MT, Silverman DT, Kraft P, Hunter DJ, Malats N, Kogevinas M, Wacholder S, Troisi R, Helman L, Fraumeni JF, Yeager M, Hoover RN, Chanock SJ. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet 45(7):799-803, 2013. e-Pub 2013. PMID: 23727862.
128. Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer 60(5):783-90, 2013. e-Pub 2013. PMID: 23335050.
129. Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ, Smith MA. Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer 60(5):791-8, 2013. e-Pub 2013. PMID: 23002019.
130. Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 60(4):633-41, 2013. e-Pub 2013. PMID: 22753001.
131. Chou AJ, Gupta R, Bell MD, Riewe KO, Meyers PA, Gorlick R. Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediatr Blood Cancer 60(4):580-6, 2013. e-Pub 2013. PMID: 23255417.
132. Warwick AB, Malempati S, Krailo M, Melemed A, Gorlick R, Ames MM, Safgren SL, Adamson PC, Blaney SM. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 60(2):237-41, 2013. e-Pub 2013. PMID: 22745043.
133. Mason GE, Aung L, Gall S, Meyers PA, Butler R, Krüg S, Kim M, Healey JH, Gorlick R. Quality of life following amputation or limb preservation in patients with lower extremity bone sarcoma. Front Oncol 3:210, 2013. e-Pub 2013. PMID: 23967402.
134. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer 59(7):1266-74, 2012. e-Pub 2012. PMID: 22315240.
135. Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 59(4):749-52, 2012. e-Pub 2012. PMID: 22052829.
136. Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH, Seibel NL, Grier HE, Gorlick R, Marina N. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer 118(18):4597-605, 2012. e-Pub 2012. PMID: 22252521.
137. Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA. Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 59(3):518-24, 2012. e-Pub 2012. PMID: 22102563.
138. Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer 59(2):246-53, 2012. e-Pub 2012. PMID: 22012946.
139. Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer 59(2):329-32, 2012. e-Pub 2012. PMID: 21922647.
140. Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal GP, Ferguson WS, Letson GD, Marcus K, Goorin A, Beardsley P, Marina N. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol 30(20):2545-51, 2012. e-Pub 2012. PMID: 22665540.
141. Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MA. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 59(1):185-8, 2012. e-Pub 2012. PMID: 21538821.
142. Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MA. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer 58(6):916-23, 2012. e-Pub 2012. PMID: 21584937.
143. Jacobs KB, Yeager M, Zhou W, Wacholder S, Wang Z, Rodriguez-Santiago B, Hutchinson A, Deng X, Liu C, Horner MJ, Cullen M, Epstein CG, Burdett L, Dean MC, Chatterjee N, Sampson J, Chung CC, Kovaks J, Gapstur SM, Stevens VL, Teras LT, Gaudet MM, Albanes D, Weinstein SJ, Virtamo J, Taylor PR, Freedman ND, Abnet CC, Goldstein AM, Hu N, Yu K, Yuan JM, Liao L, Ding T, Qiao YL, Gao YT, Koh WP, Xiang YB, Tang ZZ, Fan JH, Aldrich MC, Amos C, Blot WJ, Bock CH, Gillanders EM, Harris CC, Haiman CA, Henderson BE, Kolonel LN, Le Marchand L, McNeill LH, Rybicki BA, Schwartz AG, Signorello LB, Spitz MR, Wiencke JK, Wrensch M, Wu X, Zanetti KA, Ziegler RG, Figueroa JD, Garcia-Closas M, Malats N, Marenne G, Prokunina-Olsson L, Baris D, Schwenn M, Johnson A, Landi MT, Goldin L, Consonni D, Bertazzi PA, Rotunno M, Rajaraman P, Andersson U, Beane Freeman LE, Berg CD, Buring JE, Butler MA, Carreon T, Feychting M, Ahlbom A, Gaziano JM, Giles GG, Hallmans G, Hankinson SE, Hartge P, Henriksson R, Inskip PD, Johansen C, Landgren A, McKean-Cowdin R, Michaud DS, Melin BS, Peters U, Ruder AM, Sesso HD, Severi G, Shu XO, Visvanathan K, White E, Wolk A, Zeleniuch-Jacquotte A, Zheng W, Silverman DT, Kogevinas M, Gonzalez JR, Villa O, Li D, Duell EJ, Risch HA, Olson SH, Kooperberg C, Wolpin BM, Jiao L, Hassan M, Wheeler W, Arslan AA, Bueno-de-Mesquita HB, Fuchs CS, Gallinger S, Gross MD, Holly EA, Klein AP, LaCroix A, Mandelson MT, Petersen G, Boutron-Ruault MC, Bracci PM, Canzian F, Chang K, Cotterchio M, Giovannucci EL, Goggins M, Hoffman Bolton JA, Jenab M, Khaw KT, Krogh V, Kurtz RC, McWilliams RR, Mendelsohn JB, Rabe KG, Riboli E, Tjønneland A, Tobias GS, Trichopoulos D, Elena JW, Yu H, Amundadottir L, Stolzenberg-Solomon RZ, Kraft P, Schumacher F, Stram D, Savage SA, Mirabello L, Andrulis IL, Wunder JS, Patiño García A, Sierrasesúmaga L, Barkauskas DA, Gorlick RG, Purdue M, Chow WH, Moore LE, Schwartz KL, Davis FG, Hsing AW, Berndt SI, Black A, Wentzensen N, Brinton LA, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 44(6):651-8, 2012. e-Pub 2012. PMID: 22561519.
144. Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer 58(5):815-8, 2012. e-Pub 2012. PMID: 22052798.
145. Kolb EA, Gorlick R, Maris JM, Keir ST, Morton CL, Wu J, Wozniak AW, Smith MA, Houghton PJ. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 58(5):729-35, 2012. e-Pub 2012. PMID: 21630428.
146. Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 58(4):636-9, 2012. e-Pub 2012. PMID: 21681929.
147. Morton CL, Maris JM, Keir ST, Gorlick R, Kolb EA, Billups CA, Wu J, Smith MA, Houghton PJ. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr Blood Cancer 58(4):566-71, 2012. e-Pub 2012. PMID: 21538824.
148. Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R, Geller DS. Cell surface receptor expression patterns in osteosarcoma. Cancer 118(3):740-9, 2012. e-Pub 2012. PMID: 21751203.
149. Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL, Teicher BA, Smith MA. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer 58(2):200-9, 2012. e-Pub 2012. PMID: 21548007.
150. Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer 58(2):191-9, 2012. e-Pub 2012. PMID: 21337679.
151. Piperdi S, Austin-Page L, Geller D, Ahluwalia M, Gorlick S, Gill J, Park A, Zhang W, Li N, Chung SH, Gorlick R. β-Catenin Does Not Confer Tumorigenicity When Introduced into Partially Transformed Human Mesenchymal Stem Cells. Sarcoma 2012:164803, 2012. e-Pub 2012. PMID: 23125530.
152. Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RB. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol 68(5):1291-304, 2011. e-Pub 2011. PMID: 21448591.
153. Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, Smith MA, Houghton PJ. Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatr Blood Cancer 57(4):606-11, 2011. e-Pub 2011. PMID: 21360651.
154. Osborne TS, Ren L, Healey JH, Shapiro LQ, Chou AJ, Gorlick RG, Hewitt SM, Khanna C. Evaluation of eIF4E expression in an osteosarcoma-specific tissue microarray. J Pediatr Hematol Oncol 33(7):524-8, 2011. e-Pub 2011. PMID: 21941146.
155. Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer 57(3):443-53, 2011. e-Pub 2011. PMID: 21744473.
156. Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ. Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer 57(2):268-74, 2011. e-Pub 2011. PMID: 21360650.
157. Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 56(4):595-603, 2011. e-Pub 2011. PMID: 21298745.
158. Meyers PA, Healey JH, Chou AJ, Wexler LH, Merola PR, Morris CD, Laquaglia MP, Kellick MG, Abramson SJ, Gorlick R. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer 117(8):1736-44, 2011. e-Pub 2011. PMID: 21472721.
159. Sowers R, Wenzel BD, Richardson C, Meyers PA, Healey JH, Levy AS, Gorlick R. Impairment of methotrexate transport is common in osteosarcoma tumor samples. Sarcoma 2011:834170, 2011. e-Pub 2011. PMID: 21234348.
160. Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer 55(6):1126-33, 2010. e-Pub 2010. PMID: 20672370.
161. Mahadeo KM, Santizo R, Baker L, Curry JO, Gorlick R, Levy AS. Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective. Pediatr Blood Cancer 55(7):1296-9, 2010. e-Pub 2010. PMID: 20949591.
162. Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Lock RB. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer 55(7):1329-37, 2010. e-Pub 2010. PMID: 20740623.
163. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 55(4):668-77, 2010. e-Pub 2010. PMID: 20806365.
164. Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, Smith MA. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer 55(2):295-303, 2010. e-Pub 2010. PMID: 20582972.
165. Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P, Gorlick R. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 55(1):67-75, 2010. e-Pub 2010. PMID: 20486173.
166. Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wu J, Smith MA. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 54(7):921-6, 2010. e-Pub 2010. PMID: 20166202.
167. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 55(1):26-34, 2010. e-Pub 2010. PMID: 20108338.
168. Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Watkins A, Smith MA, Lock RB. Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer 54(5):707-15, 2010. e-Pub 2010. PMID: 20017204.
169. Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, Watkins AE, Houghton PJ. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer 54(2):307-10, 2010. e-Pub 2010. PMID: 19856388.
170. Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 9(1):101-12, 2010. e-Pub 2010. PMID: 20053767.
171. Carol H, Lock R, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer 53(7):1255-63, 2009. e-Pub 2009. PMID: 19554570.
172. Nathan SS, Huvos AG, Casas-Ganem JE, Yang R, Linkov I, Sowers R, DiResta GR, Gorlick R, Healey JH. Tumour interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. Ann Acad Med Singapore 38(12):1041-7, 2009. e-Pub 2009. PMID: 20052438.
173. Abdeen A, Chou AJ, Healey JH, Khanna C, Osborne TS, Hewitt SM, Kim M, Wang D, Moody K, Gorlick R. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 115(22):5243-50, 2009. e-Pub 2009. PMID: 19670450.
174. Li N, Yang R, Zhang W, Dorfman H, Rao P, Gorlick R. Genetically transforming human mesenchymal stem cells to sarcomas: changes in cellular phenotype and multilineage differentiation potential. Cancer 115(20):4795-806, 2009. e-Pub 2009. PMID: 19593798.
175. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, Stewart C, Keir ST, Lock R, Carol H, Reynolds CP, Maris JM, Wu J, Smith MA. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 53(4):594-8, 2009. e-Pub 2009. PMID: 19554571.
176. Morton CL, Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA. Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr Blood Cancer 53(3):509-12, 2009. e-Pub 2009. PMID: 19418543.
177. Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, Maris JM, Reynolds CP, Gorlick R, Kolb EA, Wu J, Smith MA. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer 53(3):505-8, 2009. e-Pub 2009. PMID: 19418547.
178. Hingorani P, Zhang W, Piperdi S, Pressman L, Lin J, Gorlick R, Kolb EA. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol 64(4):733-40, 2009. e-Pub 2009. PMID: 19224214.
179. Humeniuk R, Menon LG, Mishra PJ, Gorlick R, Sowers R, Rode W, Pizzorno G, Cheng YC, Kemeny N, Bertino JR, Banerjee D. Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther 8(5):1037-44, 2009. e-Pub 2009. PMID: 19383847.
180. Hingorani P, Zhang W, Gorlick R, Kolb EA. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res 15(10):3416-22, 2009. e-Pub 2009. PMID: 19447875.
181. Smith MA, Morton CL, Carol H, Gorlick RG, Kang MH, Keir ST, Kolb EA, Lock RB, Maris JM, Houghton PJ. Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A. J Clin Oncol 27(15_suppl):10015, 2009. e-Pub 2009. PMID: 27962529.
182. Ren L, Hong SH, Cassavaugh J, Osborne T, Chou AJ, Kim SY, Gorlick R, Hewitt SM, Khanna C. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene 28(6):792-802, 2009. e-Pub 2009. PMID: 19060919.
183. Levy AS, Meyers PA, Wexler LH, Jakacki R, Angiolillo A, Ringuette SN, Cohen MB, Gorlick R. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Cancer 115(1):207-16, 2009. e-Pub 2009. PMID: 19090012.
184. Nathan SS, Huvos AG, Casas-Ganem JE, Yang R, Linkov I, Sowers R, DiResta GR, Gorlick R, Healey JH. Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J Orthop Res 26(11):1520-5, 2008. e-Pub 2008. PMID: 18473395.
185. Yang R, Piperdi S, Gorlick R. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res 14(20):6396-404, 2008. e-Pub 2008. PMID: 18927278.
186. Yang R, Qin J, Hoang BH, Healey JH, Gorlick R. Polymorphisms and methylation of the reduced folate carrier in osteosarcoma. Clin Orthop Relat Res 466(9):2046-51, 2008. e-Pub 2008. PMID: 18528741.
187. Mizobuchi H, García-Castellano JM, Philip S, Healey JH, Gorlick R. Hypoxia markers in human osteosarcoma: an exploratory study. Clin Orthop Relat Res 466(9):2052-9, 2008. e-Pub 2008. PMID: 18528739.
188. Meyer JS, Nadel HR, Marina N, Womer RB, Brown KL, Eary JF, Gorlick R, Grier HE, Randall RL, Lawlor ER, Lessnick SL, Schomberg PJ, Kailo MD. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 51(2):163-70, 2008. e-Pub 2008. PMID: 18454470.
189. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 14(14):4572-83, 2008. e-Pub 2008. PMID: 18628472.
190. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 50(6):1181-9, 2008. e-Pub 2008. PMID: 18085673.
191. Lu XY, Lu Y, Zhao YJ, Jaeweon K, Kang J, Xiao-Nan L, Ge G, Meyer R, Perlaky L, Hicks J, Chintagumpala M, Cai WW, Ladanyi M, Gorlick R, Lau CC, Pati D, Sheldon M, Rao PH. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res 6(6):937-46, 2008. e-Pub 2008. PMID: 18567798.
192. Zelcer S, Kellick M, Wexler LH, Gorlick R, Meyers PA. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue. Pediatr Blood Cancer 50(6):1176-80, 2008. e-Pub 2008. PMID: 18266225.
193. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50(6):1190-7, 2008. e-Pub 2008. PMID: 18260118.
194. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 50(6):1198-206, 2008. e-Pub 2008. PMID: 17914733.
195. Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer 50(5):992-1000, 2008. e-Pub 2008. PMID: 17554786.
196. Yang R, Li WW, Hoang BH, Kim H, Banerjee D, Kheradpour A, Healey JH, Meyers PA, Bertino JR, Gorlick R. Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. BMC Cancer 8:124, 2008. e-Pub 2008. PMID: 18452618.
197. Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, Huvos AG, Sowers R, Meyers PA, Healey JH, Gorlick R. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 112(10):2119-29, 2008. e-Pub 2008. PMID: 18338812.
198. Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50(4):799-805, 2008. e-Pub 2008. PMID: 17635004.
199. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 50(3):581-7, 2008. e-Pub 2008. PMID: 17457854.
200. Gorlick RG, Abramson DH, Sowers R, Mazza BA, Dunkel IJ. Impairments in antifolate transport are common in retinoblastoma tumor samples. Pediatr Blood Cancer 50(3):573-6, 2008. e-Pub 2008. PMID: 17554792.
201. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 49(7):928-40, 2007. e-Pub 2007. PMID: 17066459.
202. Yu J, Chou AJ, Lennox A, Kleiman P, Wexler LH, Meyers PA, Gorlick R. Loss of antibody titers and effectiveness of revaccination in post-chemotherapy pediatric sarcoma patients. Pediatr Blood Cancer 49(5):656-60, 2007. e-Pub 2007. PMID: 17554790.
203. Yang R, Hoang BH, Kubo T, Kawano H, Chou A, Sowers R, Huvos AG, Meyers PA, Healey JH, Gorlick R. Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 121(5):943-54, 2007. e-Pub 2007. PMID: 17410535.
204. Guo Y, Zi X, Koontz Z, Kim A, Xie J, Gorlick R, Holcombe RF, Hoang BH. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res 25(7):964-71, 2007. e-Pub 2007. PMID: 17318900.
205. Yang R, Kolb EA, Qin J, Chou A, Sowers R, Hoang B, Healey JH, Huvos AG, Meyers PA, Gorlick R. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res 13(9):2557-67, 2007. e-Pub 2007. PMID: 17473184.
206. Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P, Group CO. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol 25(15):2057-62, 2007. e-Pub 2007. PMID: 17513810.
207. Deshpande AM, Akunowicz JD, Reveles XT, Patel BB, Saria EA, Gorlick RG, Naylor SL, Leach RJ, Hansen MF. PHC3, a component of the hPRC-H complex, associates with E2F6 during G0 and is lost in osteosarcoma tumors. Oncogene 26(12):1714-22, 2007. e-Pub 2007. PMID: 17001316.
208. Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, Wei JS, Smith MA, Houghton P, Morton C, Reynolds CP, Lock R, Gorlick R, Khanna C, Thiele CJ, Takikita M, Catchpoole D, Hewitt SM, Khan J. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 67(1):32-40, 2007. e-Pub 2007. PMID: 17210681.
209. Nathan SS, Gorlick R, Bukata S, Chou A, Morris CD, Boland PJ, Huvos AG, Meyers PA, Healey JH. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis. Cancer 107(7):1607-16, 2006. e-Pub 2006. PMID: 16933325.
210. Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 24(18):2885-90, 2006. e-Pub 2006. PMID: 16682723.
211. Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, LaQuaglia MP, Huvos AG, Meyers PA. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104(10):2214-21, 2005. e-Pub 2005. PMID: 16206297.
212. Diresta GR, Nathan SS, Manoso MW, Casas-Ganem J, Wyatt C, Kubo T, Boland PJ, Athanasian EA, Miodownik J, Gorlick R, Healey JH. Cell proliferation of cultured human cancer cells are affected by the elevated tumor pressures that exist in vivo. Ann Biomed Eng 33(9):1270-80, 2005. e-Pub 2005. PMID: 16133932.
213. Zelcer S, Kellick M, Wexler LH, Shi W, Sankaran M, Lo S, Healey J, Huvos AG, Meyers PA, Gorlick R. Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 44(7):638-42, 2005. e-Pub 2005. PMID: 15704189.
214. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Huvos AG, Healey JH, Gorlick R. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 11(7):2561-7, 2005. e-Pub 2005. PMID: 15814634.
215. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, Macdonald TJ, Gorlick R, Stephan DA. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65(5):1748-54, 2005. e-Pub 2005. PMID: 15753370.
216. Nathan SS, DiResta GR, Casas-Ganem JE, Hoang BH, Sowers R, Yang R, Huvos AG, Gorlick R, Healey JH. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 11(6):2389-97, 2005. e-Pub 2005. PMID: 15788690.
217. Spees WM, Gade TP, Yang G, Tong WP, Bornmann WG, Gorlick R, Koutcher JA. An 19F magnetic resonance-based in vivo assay of solid tumor methotrexate resistance: proof of principle. Clin Cancer Res 11(4):1454-61, 2005. e-Pub 2005. PMID: 15746046.
218. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 23(3):548-58, 2005. e-Pub 2005. PMID: 15659501.
219. Flintoff WF, Sadlish H, Gorlick R, Yang R, Williams FM. Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas. Biochim Biophys Acta 1690(2):110-7, 2004. e-Pub 2004. PMID: 15469899.
220. Ulaner GA, Hoffman AR, Otero J, Huang HY, Zhao Z, Mazumdar M, Gorlick R, Meyers P, Healey JH, Ladanyi M. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 41(2):155-62, 2004. e-Pub 2004. PMID: 15287028.
221. Hoang BH, Dyke JP, Koutcher JA, Huvos AG, Mizobuchi H, Mazza BA, Gorlick R, Healey JH. VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI. Clin Orthop Relat Res(426):32-8, 2004. e-Pub 2004. PMID: 15346048.
222. Man TK, Lu XY, Jaeweon K, Perlaky L, Harris CP, Shah S, Ladanyi M, Gorlick R, Lau CC, Rao PH. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4:45, 2004. e-Pub 2004. PMID: 15298715.
223. Iwamoto M, Banerjee D, Menon LG, Jurkiewicz A, Rao PH, Kemeny NE, Fong Y, Jhanwar SC, Gorlick R, Bertino JR. Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biol Ther 3(4):395-9, 2004. e-Pub 2004. PMID: 14726656.
224. Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza B, Meyers PA, Gorlick R. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 64(8):2734-9, 2004. e-Pub 2004. PMID: 15087387.
225. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos AG, Meyers PA, Gorlick R. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109(1):106-11, 2004. e-Pub 2004. PMID: 14735475.
226. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10(2):182-6, 2004. e-Pub 2004. PMID: 14704791.
227. Chi SN, Conklin LS, Qin J, Meyers PA, Huvos AG, Healey JH, Gorlick R. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 42(1):46-51, 2004. e-Pub 2004. PMID: 14752794.
228. Lau CC, Harris CP, Lu XY, Perlaky L, Gogineni S, Chintagumpala M, Hicks J, Johnson ME, Davino NA, Huvos AG, Meyers PA, Healy JH, Gorlick R, Rao PH. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 39(1):11-21, 2004. e-Pub 2004. PMID: 14603437.
229. Li W, Su D, Mizobuchi H, Martin DS, Gu B, Gorlick R, Cole P, Bertino JR. Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. Oncol Res 14(7-8):373-9, 2004. e-Pub 2004. PMID: 15301428.
230. Zakian KL, Shukla-Dave A, Meyers P, Gorlick R, Healey J, Thaler HT, Huvos AG, Panicek DM, Koutcher JA. Identification of prognostic markers in bone sarcomas using proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res 63(24):9042-7, 2003. e-Pub 2003. PMID: 14695223.
231. Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, Barany F, Ladanyi M, Gorlick R, Levine AJ. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A 100(20):11547-52, 2003. e-Pub 2003. PMID: 12972634.
232. Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP, Huvos AG, Qin J, Vu HT, Wexler L, Wolden S, Meyers PA. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 21(18):3423-30, 2003. e-Pub 2003. PMID: 12972518.
233. Levy AS, Sather HN, Steinherz PG, Sowers R, La M, Moscow JA, Gaynon PS, Uckun FM, Bertino JR, Gorlick R, Group Study CC. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study. J Pediatr Hematol Oncol 25(9):688-95, 2003. e-Pub 2003. PMID: 12972803.
234. Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, Wexler L, Demetri GD, Healey JH, Huvos AG, Goorin AM, Bagatell R, Ruiz-Casado A, Guzman C, Jimeno J, Harmon D. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98(4):832-40, 2003. e-Pub 2003. PMID: 12910529.
235. Dyke JP, Panicek DM, Healey JH, Meyers PA, Huvos AG, Schwartz LH, Thaler HT, Tofts PS, Gorlick R, Koutcher JA, Ballon D. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 228(1):271-8, 2003. e-Pub 2003. PMID: 12832588.
236. Sowers R, Toguchida J, Qin J, Meyers PA, Healey JH, Huvos A, Banerjee D, Bertino JR, Gorlick R. mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther 2(6):535-41, 2003. e-Pub 2003. PMID: 12813132.
237. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, Ladanyi M. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63(8):1759-63, 2003. e-Pub 2003. PMID: 12702558.
238. Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, Yang Y, Gorlick R, Meyers P, Healey J, Ladanyi M, Hoffman AR. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 12(5):535-49, 2003. e-Pub 2003. PMID: 12588801.
239. Yang R, Sowers R, Mazza B, Healey JH, Huvos A, Grier H, Bernstein M, Beardsley GP, Krailo MD, Devidas M, Bertino JR, Meyers PA, Gorlick R. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res 9(2):837-44, 2003. e-Pub 2003. PMID: 12576457.
240. Aung L, Gorlick R, Healey JH, Shi W, Thaler HT, Shorter NA, Huvos AG, Meyers PA. Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma. J Clin Oncol 21(2):342-8, 2003. e-Pub 2003. PMID: 12525528.
241. Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 8(12):3646-57, 2002. e-Pub 2002. PMID: 12473573.
242. Levy AS, Cunningham-Rundles S, Mazza B, Simm M, Gorlick R, Bussel J. High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. Br J Haematol 118(3):836-8, 2002. e-Pub 2002. PMID: 12181055.
243. García-Castellano JM, Villanueva A, Healey JH, Sowers R, Cordon-Cardo C, Huvos A, Bertino JR, Meyers P, Gorlick R. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 8(3):782-7, 2002. e-Pub 2002. PMID: 11895909.
244. Gorlick R, Liao AC, Antonescu C, Huvos AG, Healey JH, Sowers R, Daras M, Calleja E, Wexler LH, Panicek D, Meyers PA, Yeh SD, Larson SM. Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma. Clin Cancer Res 7(10):3065-70, 2001. e-Pub 2001. PMID: 11595696.
245. Cole PD, Kamen BA, Gorlick R, Banerjee D, Smith AK, Magill E, Bertino JR. Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res 61(11):4599-604, 2001. e-Pub 2001. PMID: 11389096.
246. Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS, Baker DL, Davis JH, Gerbing RB, Grovas A, Herzog CE, Lindsley KL, Liu-Mares W, Nachman JB, Sieger L, Wadman J, Gorlick RG. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 19(11):2812-20, 2001. e-Pub 2001. PMID: 11387352.
247. Morris CD, Gorlick R, Huvos G, Heller G, Meyers PA, Healey JH. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res(382):59-65, 2001. e-Pub 2001. PMID: 11154005.
248. Longo GS, Izzo J, Gorlick R, Banerjee D, Jhanwar SC, Bertino JR. Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase. Oncol Res 12(8):309-14, 2001. e-Pub 2001. PMID: 11589301.
249. Banerjee D, Gorlick R, Liefshitz A, Danenberg K, Danenberg PC, Danenberg PV, Klimstra D, Jhanwar S, Cordon-Cardo C, Fong Y, Kemeny N, Bertino JR. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res 60(9):2365-7, 2000. e-Pub 2000. PMID: 10811110.
250. Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17(9):2781-8, 1999. e-Pub 1999. PMID: 10561353.
251. Guo W, Gorlick R, Ladanyi M, Meyers PA, Huvos AG, Bertino JR, Healey JH. Expression of bone morphogenetic proteins and receptors in sarcomas. Clin Orthop Relat Res(365):175-83, 1999. e-Pub 1999. PMID: 10627702.
252. Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR, Gorlick R. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 5(3):621-7, 1999. e-Pub 1999. PMID: 10100715.
253. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16(7):2452-8, 1998. e-Pub 1998. PMID: 9667263.
254. Gorlick R, Meyers P, Kellick M, Bertino JR. Monitoring methotrexate levels in osteosarcoma. J Clin Oncol 16(6):2290-1, 1998. e-Pub 1998. PMID: 9626240.
255. Gorlick R, Metzger R, Danenberg KD, Salonga D, Miles JS, Longo GS, Fu J, Banerjee D, Klimstra D, Jhanwar S, Danenberg PV, Kemeny N, Bertino JR. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol 16(4):1465-9, 1998. e-Pub 1998. PMID: 9552053.
256. Longo GS, Izzo J, Chang YM, Tong WP, Zielinski Z, Gorlick R, Chou TC, Bertino JR. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity. Clin Cancer Res 4(2):469-73, 1998. e-Pub 1998. PMID: 9516938.
257. Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, Flintoff WF, Bertino JR. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89(3):1013-8, 1997. e-Pub 1997. PMID: 9028333.
258. Longo GS, Gorlick R, Tong WP, Lin S, Steinherz P, Bertino JR. gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol Res 9(5):259-63, 1997. e-Pub 1997. PMID: 9306433.
259. Hochhauser D, Schnieders B, Ercikan-Abali E, Gorlick R, Muise-Helmericks R, Li WW, Fan J, Banerjee D, Bertino JR. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst 88(18):1269-75, 1996. e-Pub 1996. PMID: 8797766.

Invited Articles

1. Hingorani P, Janeway K, Crompton BD, Kadoch C, Mackall CL, Khan J, Shern JF, Schiffman J, Mirabello L, Savage SA, Ladanyi M, Meltzer P, Bult CJ, Adamson PC, Lupo PJ, Mody R, DuBois SG, Parsons DW, Khanna C, Lau C, Hawkins DS, Randall RL, Smith M, Sorensen PH, Plon SE, Skapek SX, Lessnick S, Gorlick R, Reed DR. Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genet 209(5):182-94, 2016. e-Pub 2016. PMID: 27132463.
2. Bishop MW, Janeway KA, Gorlick R. Future directions in the treatment of osteosarcoma. Curr Opin Pediatr 28(1):26-33, 2016. e-Pub 2016. PMID: 26626558.
3. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol 33(27):3029-35, 2015. e-Pub 2015. PMID: 26304877.
4. Glover J, Krailo M, Tello T, Marina N, Janeway K, Barkauskas D, Fan TM, Gorlick R, Khanna C, Group COG. A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation. Pediatr Blood Cancer 62(3):450-5, 2015. e-Pub 2015. PMID: 25611047.
5. Gill J, Geller D, Gorlick R. HER-2 involvement in osteosarcoma. Adv Exp Med Biol 804:161-77, 2014. e-Pub 2014. PMID: 24924174.
6. Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N, Committee COG. Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer 60(6):1009-15, 2013. e-Pub 2013. PMID: 23255238.
7. Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther 137(1):89-99, 2013. e-Pub 2013. PMID: 22983152.
8. Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL, Committee COG. A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group. Front Oncol 3:57, 2013. e-Pub 2013. PMID: 23519678.
9. Sampson VB, Gorlick R, Kamara D, Anders Kolb E. A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol 3:132, 2013. e-Pub 2013. PMID: 23755370.
10. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8(10):705-18, 2010. e-Pub 2010. PMID: 21317869.
11. Gorlick R, Khanna C. Osteosarcoma. J Bone Miner Res 25(4):683-91, 2010. e-Pub 2010. PMID: 20205169.
12. Geller DS, Gorlick R. HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies. Expert Opin Pharmacother 11(1):51-61, 2010. e-Pub 2010. PMID: 20001429.
13. Kolb EA, Gorlick R. Development of IGF-IR Inhibitors in Pediatric Sarcomas. Curr Oncol Rep 11(4):307-13, 2009. e-Pub 2009. PMID: 19508836.
14. O'Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 9(4):511-23, 2009. e-Pub 2009. PMID: 19374604.
15. Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 152:467-78, 2009. e-Pub 2009. PMID: 20213409.
16. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here?. Paediatr Drugs 10(5):315-27, 2008. e-Pub 2008. PMID: 18754698.
17. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6(7):1075-85, 2006. e-Pub 2006. PMID: 16831079.
18. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9(4):422-41, 2004. e-Pub 2004. PMID: 15266096.
19. Gorlick R. Osteosarcoma: clinical practice and the expanding role of biology. J Musculoskelet Neuronal Interact 2(6):549-51, 2002. e-Pub 2002. PMID: 15758391.
20. Gorlick R, Banerjee D. Fluoropyrimidine resistance in colon cancer. Expert Rev Anticancer Ther 2(4):409-16, 2002. e-Pub 2002. PMID: 12647984.
21. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 1587(2-3):164-73, 2002. e-Pub 2002. PMID: 12084458.
22. Gorlick R, Bertino JR. Drug resistance in colon cancer. Semin Oncol 26(6):606-11, 1999. e-Pub 1999. PMID: 10606253.
23. Gorlick R, Cole P, Banerjee D, Longo G, Li WW, Hochhauser D, Bertino JR. Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation. Adv Exp Med Biol 457:543-50, 1999. e-Pub 1999. PMID: 10500832.
24. Longo GS, Gorlick R, Tong WP, Ercikan E, Bertino JR. Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Blood 90(3):1241-5, 1997. e-Pub 1997. PMID: 9242558.
25. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 44(4):973-89, 1997. e-Pub 1997. PMID: 9286295.
26. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335(14):1041-8, 1996. e-Pub 1996. PMID: 8793930.
27. Bertino JR, Göker E, Gorlick R, Li WW, Banerjee D. Resistance mechanisms to methotrexate in tumors. Stem Cells 14(1):5-9, 1996. e-Pub 1996. PMID: 8820944.
28. Bertino JR, Göker E, Gorlick R, Li WW, Banerjee D. Resistance Mechanisms to Methotrexate in Tumors. Oncologist 1(4):223-226, 1996. e-Pub 1996. PMID: 10387992.

Review Articles

1. Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJR, Crompton BD, DuBois SG, Shukla N, Leavey PJ, Lessnick SL, Kovar H, Delattre O, Grünewald TGP, Antonescu CR, Roberts RD, Toretsky JA, Tirode F, Gorlick R, Janeway KA, Reed D, Lawlor ER, Grohar PJ. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol 6(1):65, 2022. e-Pub 2022. PMID: 36115869.
2. Jia Z, Ragoonanan D, Mahadeo KM, Gill J, Gorlick R, Shpal E, Li S. IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines. Front Immunol 13:952231, 2022. e-Pub 2022. PMID: 36203573.
3. Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol 18(10):609-624, 2021. e-Pub 2021. PMID: 34131316.
4. Gill J, Hingorani P, Roth M, Gorlick R. HER2-Targeted Therapy in Osteosarcoma. Adv Exp Med Biol 1257:55-66, 2020. e-Pub 2020. PMID: 32483730.
5. Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer 125(20):3514-3525, 2019. e-Pub 2019. PMID: 31355930.
6. Bailey K, Cost C, Davis I, Glade-Bender J, Grohar P, Houghton P, Isakoff M, Stewart E, Laack N, Yustein J, Reed D, Janeway K, Gorlick R, Lessnick S, DuBois S, Hingorani P. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Res 8, 2019. e-Pub 2019. PMID: 31031965.
7. Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther 18(1):39-50, 2018. e-Pub 2018. PMID: 29210294.
8. Davis LE, Janeway KA, Weiss AR, Chen YE, Scharschmidt TJ, Krailo M, Glade Bender JL, Kopp LM, Patel SR, Schwartz GK, Horvath LE, Hawkins DS, Chuk MK, Reinke DK, Gorlick RG, Randall RL. Clinical trial enrollment of adolescents and young adults with sarcoma. Cancer 123(18):3434-3440, 2017. e-Pub 2017. PMID: 28493547.
9. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 9(15):5442-53, 2003. e-Pub 2003. PMID: 14654523.

Other Articles

1. Garfein E, Doscher M, Tepper O, Gill J, Gorlick R, Smith RV Reconstruction of the pediatric midface following oncologic resection. J Reconstr Microsurg 31(5):336-42, 2015. PMID: 25803408.
2. Conroy EM, Frimer M, Karabakhtsian RG, Gorlick R, Goldberg GL Vulvar fibromatosis: a clinical enigma. J Pediatr Hematol Oncol 37(1):63-7, 2015. PMID: 25238226.
3. Crocco L, Gorlick R, Geller DS Current practice managements regarding thromboembolic prophylaxis within the pediatric sarcoma patient population. J Pediatr Hematol Oncol 35(1):28-31, 2013. PMID: 22995922.
4. Shakked RJ, Geller DS, Gorlick R, Dorfman HD Mesenchymal chondrosarcoma: clinicopathologic study of 20 cases. Arch Pathol Lab Med 136(1):61-75, 2012. PMID: 22208489.
5. Lall A, Hohn E, Kim MY, Gorlick RG, Abraham JA, Geller DS Comparison of Surface Area across the Allograft-Host Junction Site Using Conventional and Navigated Osteotomy Technique. Sarcoma 2012:197540, 2012. PMID: 23319879.
6. Green MC, Dorfman HD, Villanueva-Siles E, Gorlick RG, Thornhill BA, Weber RV, Geller DS Aggressively recurrent infantile myofibroma of the axilla and shoulder girdle. Skeletal Radiol 40(3):357-61, 2011. PMID: 20978757.
7. Butros LJ, Phillip S, Chou A, Meyers PA, Huvos AG, Healey JH, Russo P, Gorlick RG Leydig cell tumor after treatment for Ewing's sarcoma. Pediatr Blood Cancer 49(7):1008-10, 2007. PMID: 16526050.
8. Oppenheimer O, Athanasian E, Meyers P, Antonescu CR, Gorlick R Malignant ectomesenchymoma in the wrist of a child: case report and review of the literature. Int J Surg Pathol 13(1):113-6, 2005. PMID: 15735865.
9. Cosetti M, Wexler LH, Calleja E, Trippett T, LaQuaglia M, Huvos AG, Gerald W, Healey JH, Meyers PA, Gorlick R Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 24(2):101-5, 2002. PMID: 11990694.
10. Antunes NL, Gorlick R, Callaja E, Lis E Numb chin syndrome in Ewing sarcoma. J Pediatr Hematol Oncol 22(6):521-3, 2000. PMID: 11132220.
11. Levy AS, Meyers P, Kellick M, Gorlick R, Tong W, Bertino JR Acute stroke-like encephalopathy associated with high-dose methotrexate impurities. J Pediatr Hematol Oncol 22(4):360-2, 2000. PMID: 10959910.
12. Orme L, Gorlick R, Meyers PA, Athanasian E, Huvos AG Osteosarcoma associated with absent thumbs: a report of two cases. J Pediatr Hematol Oncol 22(1):73-7, 2000. PMID: 10695826.
13. Fein-Levy C, Gorlick R, Meyers PA, Healey J, Huvos AG Ewing's sarcoma in a patient with congenital optic atrophy. J Pediatr Hematol Oncol 20(6):577-9, 1998. PMID: 9856684.
14. Spurney C, Gorlick R, Meyers PA, Healey JH, Huvos AG Multicentric osteosarcoma, Rothmund-Thomson syndrome, and secondary nasopharyngeal non-Hodgkin's lymphoma: a case report and review of the literature. J Pediatr Hematol Oncol 20(5):494-7, 1998. PMID: 9787328.
15. Argiris A, Longo GS, Gorlick R, Tong W, Steinherz P, Bertino JR Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia. Leukemia 11(6):886-9, 1997. PMID: 9177445.

Editorials

1. Janeway KA, Gorlick R. The case for informative phase 2 trials in osteosarcoma. Lancet Oncol 17(8):1022-3, 2016. PMID: 27511145.
2. Isakoff MS, Goldsby R, Villaluna D, Krailo MD, Gorlick R, Doski JJ, Womer RB, Janeway KA. Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer 63(2):370-1, 2016. PMID: 26376351.
3. Geller DS, Gill J, Roth M, Gorlick R. To B(MP-2) or Not To B(MP-2): Cytokines and Tumor Surgery Letter. Clin Cancer Res 21(17):4022, 2015. PMID: 26330506.
4. Hohenberger P, Gorlick R, Gronchi A. Collaborations between SSO and the Connective Tissue Oncology Society (CTOS) series. Ann Surg Oncol 22(9):2815-6, 2015. PMID: 26148756.
5. Toretsky JA, Gorlick R. IGF-1R targeted treatment of sarcoma. Lancet Oncol 11(2):105-6, 2010. PMID: 20036195.
6. Marina N, Gorlick R. Immune approaches to treating osteosarcoma. Cancer Biol Ther 8(10):981-3, 2009. PMID: 19395866.
7. Jaffe N, Gorlick R. High-dose methotrexate in osteosarcoma: let the questions surcease--time for final acceptance. J Clin Oncol 26(27):4365-6, 2008. PMID: 18802144.
8. Gorlick R, Meyers PA. Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol 25(11):840-1, 2003. PMID: 14608191.
9. Aung L, Gorlick RG, Shi W, Thaler H, Shorter NA, Healey JH, Huvos AG, Meyers PA. Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience. Cancer 95(8):1728-34, 2002. PMID: 12365021.

Book Chapters

1. Gorlick R, Bielack S, Teot L, Meyer J, Randall L, Marina N. , Osteosarcoma: Biology, Diagnosis, Treatment and Remaining Challenge. In: Principles and Practice of Pediatric Oncology. Lippincott, 1015-1044, 2011.
2. Dubois S, Janeway K, Gorlick R, Marina N. Malignant Bone Tumors. In: Manual of Pediatric Hematology and Oncology. 5th Edition. Elsevier, 739-758, 2011.
3. Gorlick R, Meyers P. Osteosarcoma. In: Rudolph’s Pediatrics. 22nd Edition. McGraw-Hill, 1637-1639, 2011.
4. Ricafort R, Gorlick R. Molecularly Targeted Therapy in Osteosarcoma. In: Molecularly Targeted Therapy for Childhood Cancer. Springer, 459-498, 2010.
5. Gorlick R, Persioglou M, Whelan J. Bone Tumours. In: Pediatric Hematology and Oncology. Wiley-Blackwell, 234-257, 2010.
6. Marina N, Gorlick R, Bielack S. Pediatric Osteosarcoma. In: Cancer in Children and Adolescents. Jones & Bartlett, 383-394, 2010.
7. Janeway K, Gorlick R, Bernstein ML. Osteosarcoma. In: Nathan and Oski’s Oncology of Infancy and Childhood. Saunders-Elsevier, 871-910, 2009.
8. Kolb EA, Gorlick R. Leukemias. In: American Academy of Pediatrics Textbook of Pediatric Care. American Academy of Pediatrics, 2231-2248, 2009.
9. Gorlick R. Current Concepts on the Molecular Biology of Osteosarcoma. In: Pediatric and Adolescent Osteosarcoma. Springer, 2009.
10. Gorlick R, Bernstein ML, Toretsky JA, Randall RL, Gebhardt MC, Teot LA, Wolden S, Marina N. Bone Tumors. In: Cancer Medicine. BC Decker, 2019-2027, 2006.
11. Gorlick R, Toretsky J, Marina N, Wolden S, Randall RL, Gebhardt M, Teot L, Bernstein M. Bone Tumors. In: Cancer Medicine. sixth edition. BC Decker, 2383-2406, 2003.
12. Gorlick R, Meyers PA. Bone Tumors. In: Encyclopedia of Cancer. Second Edition. Academic Press, 229-237, 2002.
13. Meyers PA, Gorlick R. General Principles of Chemotherapy. In: Orthopedic Knowledge Update: Musculoskeletal Tumors. American Academy of Orthopaedic Surgeons, 49-58, 2002.
14. Gorlick R. Methotrexate, its mechanism of action in malignant disease and mechanisms of resistance by malignant cells. In: Methotrexate. Birkhäuser Verlag, 9-29, 2000.
15. Gorlick R, Bertino JR. Clinical pharmacology and resistance to dihyrdrofolate reductase inhibitors. In: Antifolate drugs: Basic research and clinical practice. The Humana Press, 37-57, 1999.
16. Goker E, Gorlick R, Bertino JR. Resistance mechanisms to antimetabolites. In: Drug resistance in the treatment of cancer. Cambridge University Press, 1-13, 1998.
17. Gorlick R. Bone Tumors in Fisher. In: Textbook of Adolescent Health Care,. American Academy of Pediatrics.